SPN 448
Alternative Names: SPN-448Latest Information Update: 28 Aug 2023
At a glance
- Originator Supernus Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research CNS disorders
Most Recent Events
- 28 Aug 2023 SPN 448 is available for licensing as of 28 Aug 2023. https://www.supernus.com/about-us
- 25 Jul 2023 Early research in CNS disorders in USA (unspecified route) prior to July 2023 (Supernus Pharmaceuticals pipeline, July 2023)